Methylglyoxal-mediated stress correlates with high metabolic activity and promotes tumor growth in colorectal cancer

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Chiavarina, Barbara ^a   Nokin, Marie Julie ^a   Bellier, Justine ^a   Durieux, Florence ^a   Bletard, Noëlla ^b   Sherer, Félicie ^c   Lovinfosse, Pierre ^b   Peulen, Olivier ^a   Verset, Laurine ^c   Dehon, Romain ^c   Demetter, Pieter ^c   Turtoi, Andrei ^a   Uchida, Koji ^d   Goldman, Serge ^c   Hustinx, Roland ^b   Delvenne, Philippe ^b   Castronovo, Vincent ^a   Bellahcène, Akeila ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

18F Fluorodeoxyglucose (18F FDG); Colorectal cancer; Glyoxalase 1; Methylglyoxal; MG adducts

Indexed keywords

METHYLGLYOXAL; CARNOSINE; FLUORODEOXYGLUCOSE F 18; GLO1 PROTEIN, HUMAN; LACTOYLGLUTATHIONE LYASE; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; COLON ADENOCARCINOMA; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; TUMOR GROWTH; WESTERN BLOTTING; AGED; ANIMAL; CANCER STAGING; CELL PROLIFERATION; CHICKEN; COHORT ANALYSIS; COLORECTAL TUMOR; DRUG EFFECTS; GLYCOLYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGICAL STRESS; POSITRON EMISSION TOMOGRAPHY; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; CARNOSINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; COHORT STUDIES; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; LACTOYLGLUTATHIONE LYASE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; PYRUVALDEHYDE; STRESS, PHYSIOLOGICAL;

EID: 85010777954     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010213     Document Type: Article

References (64)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917.
2. Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 104–117.
3. Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361, 2449–2460.
4. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O’Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757–1765.
5. Amado, R.G.; Wolf, M.; Peeters, M.; van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626–1634.
6. Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11, 85–95.
7. Li, R.; Grimm, S.A.; Chrysovergis, K.; Kosak, J.; Wang, X.; Du, Y.; Burkholder, A.; Janardhan, K.; Mav, D.; Shah, R.; et al. Obesity, rather than diet, drives epigenomic alterations in colonic epithelium resembling cancer progression. Cell Metab. 2014, 19, 702–711.
8. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269–270.
9. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033.
10. Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297–308.
11. Fang, S.; Fang, X. Advances in glucose metabolism research in colorectal cancer. Biomed. Rep. 2016, 5, 289–295.
12. Richard, J.P. Mechanism for the formation of methylglyoxal from triosephosphates. Biochem. Soc. Trans. 1993, 21, 549–553.
13. Thornalley, P.J. Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification—A role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 1996, 27, 565–573.
14. Thornalley, P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems—Role in ageing and disease. Drug Metab. Drug Interact. 2008, 23, 125–150.
15. Thornalley, P.J. Dicarbonyl intermediates in the maillard reaction. Ann. N. Y. Acad. Sci. 2005, 1043, 111–117.
16. Xue, M.; Rabbani, N.; Thornalley, P.J. Glyoxalase in ageing. Semin. Cell Dev. Biol. 2011, 22, 293–301.
17. Rabbani, N.; Thornalley, P.J. Glyoxalase in diabetes, obesity and related disorders. Semin. Cell Dev. Biol. 2011, 22, 309–317.
18. Ranganathan, S.; Tew, K.D. Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochim. Biophys. Acta 1993, 1182, 311–316.
19. Davidson, S.D.; Cherry, J.P.; Choudhury, M.S.; Tazaki, H.; Mallouh, C.; Konno, S. Glyoxalase I activity in human prostate cancer: A potential marker and importance in chemotherapy. J. Urol. 1999, 161, 690–691.
20. Romanuik, T.L.; Ueda, T.; Le, N.; Haile, S.; Yong, T.M.; Thomson, T.; Vessella, R.L.; Sadar, M.D. Novel biomarkers for prostate cancer including noncoding transcripts. Am. J. Pathol. 2009, 175, 2264–2276.
21. Sakamoto, H.; Mashima, T.; Sato, S.; Hashimoto, Y.; Yamori, T.; Tsuruo, T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin. Cancer Res. 2001, 7, 2513–2518.
22. Bair, W.B., III; Cabello, C.M.; Uchida, K.; Bause, A.S.; Wondrak, G.T. GLO1 overexpression in human malignant melanoma. Melanoma Res. 2010, 20, 85–96.
23. Rulli, A.; Carli, L.; Romani, R.; Baroni, T.; Giovannini, E.; Rosi, G.; Talesa, V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res. Treat. 2001, 66, 67–72.
24. Santarius, T.; Bignell, G.R.; Greenman, C.D.; Widaa, S.; Chen, L.; Mahoney, C.L.; Butler, A.; Edkins, S.; Waris, S.; Thornalley, P.J.; et al. GLO1—A novel amplified gene in human cancer. Genes Chromosom. Cancer 2010, 49, 711–725.
25. Zhang, S.; Liang, X.; Zheng, X.; Huang, H.; Chen, X.;Wu, K.;Wang, B.; Ma, S. GLO1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7, 2079–2090.
26. Cheng, W. L.; Tsai, M. M.; Tsai, C. Y.; Huang, Y. H.; Chen, C. Y.; Chi, H. C.; Tseng, Y. H.; Chao, I. W.; Lin, W. C.; Wu, S. M.; et al. Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS ONE 2012, 7, e34352.
27. Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Katai, H.; Taniguchi, H.; Yanagihara, K.; Imoto, I.; et al. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene 2015, 34, 1196–1206.
28. Fonseca-Sanchez, M.A.; Rodriguez Cuevas, S.; Mendoza-Hernandez, G.; Bautista-Pina, V.; Arechaga Ocampo, E.; Hidalgo Miranda, A.; Quintanar Jurado, V.; Marchat, L.A.; Alvarez-Sanchez, E.; Perez Plasencia, C.; et al. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int. J. Oncol. 2012, 41, 670–680.
29. Sakamoto, H.; Mashima, T.; Kizaki, A.; Dan, S.; Hashimoto, Y.; Naito, M.; Tsuruo, T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000, 95, 3214–3218.
30. Thornalley, P.J.; Rabbani, N. Glyoxalase in tumourigenesis and multidrug resistance. Semin. Cell Dev. Biol. 2011, 22, 318–325.
31. Jadvar, H.; Alavi, A.; Gambhir, S.S. 18F-FDG uptake in lung, breast, and colon cancers: Molecular biology correlates and disease characterization. J. Nucl. Med. 2009, 50, 1820–1827.
32. De Geus-Oei, L.F.; Vriens, D.; van Laarhoven, H.W.; van der Graaf, W.T.; Oyen, W.J. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J. Nucl. Med. 2009, 50 (Suppl. 1), 43S–54S.
33. Shipanova, I.N.; Glomb, M.A.; Nagaraj, R.H. Protein modification by methylglyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. 1997, 344, 29–36.
34. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813–820.
35. Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006, 114, 597–605.
36. Turk, Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. 2010, 59, 147–156.
37. Dobler, D.; Ahmed, N.; Song, L.; Eboigbodin, K.E.; Thornalley, P.J. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006, 55, 1961–1969.
38. Bierhaus, A.; Fleming, T.; Stoyanov, S.; Leffler, A.; Babes, A.; Neacsu, C.; Sauer, S.K.; Eberhardt, M.; Schnolzer, M.; Lasitschka, F.; et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 2012, 18, 926–933.
39. Yan, S.F.; Ramasamy, R.; Naka, Y.; Schmidt, A.M. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 2003, 93, 1159–1169.
40. Rabbani, N.; Thornalley, P.J. The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes 2014, 63, 50–52.
41. Van Heijst, J.W.; Niessen, H.W.; Hoekman, K.; Schalkwijk, C.G. Advanced glycation end products in human cancer tissues: Detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann. N. Y. Acad. Sci. 2005, 1043, 725–733.
42. Chiavarina, B.; Nokin, M.J.; Durieux, F.; Bianchi, E.; Turtoi, A.; Peulen, O.; Peixoto, P.; Irigaray, P.; Uchida, K.; Belpomme, D.; et al. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 2014, 5, 5472–5482.
43. Van Heijst, J.W.; Niessen, H.W.; Musters, R.J.; van Hinsbergh, V.W.; Hoekman, K.; Schalkwijk, C.G. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: A possible mechanism for evasion of apoptosis. Cancer Lett. 2006, 241, 309–319.
44. Oya-Ito, T.; Naito, Y.; Takagi, T.; Handa, O.; Matsui, H.; Yamada, M.; Shima, K.; Yoshikawa, T. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim. Biophys. Acta 2011, 1812, 769–781.
45. Sakellariou, S.; Fragkou, P.; Levidou, G.; Gargalionis, A.N.; Piperi, C.; Dalagiorgou, G.; Adamopoulos, C.; Saetta, A.; Agrogiannis, G.; Theohari, I.; et al. Clinical significance of AGE-RAGE axis in colorectal cancer: Associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer 2016, 16, 174.
46. Maessen, D.E.; Stehouwer, C.D.; Schalkwijk, C.G. The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. Clin. Sci. 2015, 128, 839–861.
47. Rampal, S.; Yang, M.H.; Sung, J.; Son, H.J.; Choi, Y.H.; Lee, J.H.; Kim, Y.H.; Chang, D.K.; Rhee, P.L.; Rhee, J.C.; et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology 2014, 147, 78.e73–87.e73.
48. Antognelli, C.; Mezzasoma, L.; Fettucciari, K.; Mearini, E.; Talesa, V.N. Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells. Prostate 2013, 73, 121–132.
49. Zender, L.; Xue, W.; Zuber, J.; Semighini, C.P.; Krasnitz, A.; Ma, B.; Zender, P.; Kubicka, S.; Luk, J.M.; Schirmacher, P.; et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008, 135, 852–864.
50. Nokin, M.J.; Durieux, F.; Peixoto, P.; Chiavarina, B.; Peulen, O.; Blomme, A.; Turtoi, A.; Costanza, B.; Smargiasso, N.; Baiwir, D.; et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife 2016, 5, e19375.
51. Hipkiss, A.R.; Cartwright, S.P.; Bromley, C.; Gross, S.R.; Bill, R.M. Carnosine: Can understanding its actions on energy metabolism and protein homeostasis inform its therapeutic potential? Chem. Cent. J. 2013, 7, 38.
52. Shi, D.; Cai, G.; Peng, J.; Li, D.; Li, X.; Xu, Y.; Cai, S. The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer. BMC Cancer 2015, 15, 991.
53. Kang, Y.; Edwards, L.G.; Thornalley, P.J. Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA G1 growth arrest and induction of apoptosis. Leuk. Res. 1996, 20, 397–405.
54. Sakamoto, H.; Mashima, T.; Yamamoto, K.; Tsuruo, T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J. Biol. Chem. 2002, 277, 45770–45775.
55. Shen, Y.; Yang, J.; Li, J.; Shi, X.; Ouyang, L.; Tian, Y.; Lu, J. Carnosine inhibits the proliferation of human gastric cancer SGC-7901 cells through both of the mitochondrial respiration and glycolysis pathways. PLoS ONE 2014, 9, e104632.
56. Renner, C.; Asperger, A.; Seyffarth, A.; Meixensberger, J.; Gebhardt, R.; Gaunitz, F. Carnosine inhibits ATP production in cells from malignant glioma. Neurol. Res. 2010, 32, 101–105.
57. Iovine, B.; Oliviero, G.; Garofalo, M.; Orefice, M.; Nocella, F.; Borbone, N.; Piccialli, V.; Centore, R.; Mazzone, M.; Piccialli, G.; et al. The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1 alpha in human colon cancer cells. PLoS ONE 2014, 9, e96755.
58. Smith, U.; Gale, E.A. Cancer and diabetes: Are we ready for prime time? Diabetologia 2010, 53, 1541–1544.
59. Giovannucci, E.; Harlan, D.M.; Archer, M.C.; Bergenstal, R.M.; Gapstur, S.M.; Habel, L.A.; Pollak, M.; Regensteiner, J.G.; Yee, D. Diabetes and cancer: A consensus report. Diabetes Care 2010, 33, 1674–1685.
60. Nakayama, K.; Nakayama, M.; Iwabuchi, M.; Terawaki, H.; Sato, T.; Kohno, M.; Ito, S. Plasma -oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am. J. Nephrol. 2008, 28, 871–878.
61. Kasznicki, J.; Sliwinska, A.; Drzewoski, J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014, 2, 57.
62. Zhang, Z.J.; Zheng, Z.J.; Kan, H.; Song, Y.; Cui, W.; Zhao, G.; Kip, K.E. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care 2011, 34, 2323–2328.
63. Oya, T.; Hattori, N.; Mizuno, Y.; Miyata, S.; Maeda, S.; Osawa, T.; Uchida, K. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 1999, 274, 18492–18502.
64. Waltregny, D.; Bellahcene, A.; Van Riet, I.; Fisher, L.W.; Young, M.; Fernandez, P.; Dewe, W.; de Leval, J.; Castronovo, V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J. Natl. Cancer Inst. 1998, 90, 1000–1008.